Floatz logo

nnc0519-0130

Chronic Kidney Disease

Novo Nordisk A/SPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB

View all 50 →

Same molecule, other indications

nnc0519-0130 is also rated in:

obesity disorderDormant
CCC
Indicative ·
53 / 100
View asset →
type 2 diabetes mellitusDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →